Debjani is a principal research scientist in the Health Care Evaluation Research department. She has extensive experience in the drug life cycle from bench and clinical research through coverage, formulary placement, and reimbursement. Her work has included biosimilars and she was part of a team that worked on the first biosimilar approval before there was a pathway. She has substantial expertise and experience across a range of health care policy topics such as the Medicare program along with Inflation Reduction Act (IRA) and Part D Redesign, coverage under Part B versus Part D, ABii and MARx databases, quality metrics and Triple Aim, Stars and audits as well as Medicare Advantage, MLR, and essential health benefits.  Her health care system reform experience includes transparency, pay-for-performance, and guidelines and quality metrics, along with Medicare and Medicaid Core Sets.

Debjani’s research work has included primary research focused on genetic pathways related to transcription factors and hepatic cancer where she developed both her knockout gene mouse line and cell line. Her secondary data analysis focused on cardiology guideline development with a focus on heart failure and pulmonary hypertension.

She has also worked extensively in the maternal health space, where she led two quality review programs with profit and loss (P&L) responsibilities and conducted hospital maternal and child reviews in national and international settings. She has also worked in the neurology measurement and reimbursement space, which included quality measures along with monoclonal antibodies directed against amyloid for the treatment of Alzheimer's Disease coverage and reimbursement.